CD274 and neoplasm: Their data provided a strong rationale to clinically explore the potential of galunisertib to enhance anti-tumor immune response, particularly, in combinations with PD-L1/PD-1 checkpoint inhibitors, and also prompted this work, studying the effect of silencing the targets using siRNA.